A recent study taking place in the US, UK, Sweden and Brazil proved Autologous Hematopoietic Stem Cell Transplantation (HCST) to be a safe and effective treatment for people with a relapsing form of Multiple Sclerosis (MS). HSCT “is more effective at preventing disease progression compared to currently used disease-modifying therapies, according to the new study published…in JAMA.” (CNN)
110 patients who had relapsing-remitting MS participated in the clinical trial. Patients were randomly given either the HSCT treatment or another DMT (disease-modifying therapy), different from the classes they had previously used.
Only three out of 55 patients receiving HSCT showed progression after a year. However, 34 out of the 55 patients who received the DMT showed progression after a year.
In the HSCT group, 2% of patients had disease progression after two years, 5% after three years, and 10% after years 4 and 5.
By contrast, in the DMT patients, almost 25% showed progression of disease after one year, more than 50% after two years, and just under 75% at five years.
What is MS?
In MS, the immune system damages the brain and spinal cord. This happens “when myelin, a white fatty coating that insulates the body’s nerves, is mistakenly labeled as a foreign invader, [and is then] attacked, and stripped from the nervous system by the immune system. Without insulation, neurons lose their important ability to conduct electrical signals.”
The cause of this happening is unclear; but 2.3 million people worldwide have been diagnosed with MS.
Symptoms of MS:
What is HCST?
The purpose of HCST is to reboot and restore the immune system.
What is involved in the procedure?
Depending on the doctor and medical center, treatment protocols vary, but the general steps are the same:
Who is eligible?
A patient must meet very specific medical criteria before being eligible for HSCT:
Clinical trials show HSCT can reduce relapses, especially for people with relapsing MS. Some patients have more stable or improved symptoms.
Patients who have progressive MS had encouraging results when treated early in their condition, when there was still evidence of inflammation. HSCT has also “been shown to slow clinical progression in a few people with early secondary progressive MS.”
HCST is not FDA-approved, but is considered experimental. Because it a very aggressive treatment, HSCT comes with high risks and complications:
Of course, the chemotherapy itself has side effects as well:
Also, patients who have a high level of disability before transplant may have more loss of mobility and worsened neurological function.
If you’re considering HSCT, talk to your neurologist to find out if it may be the right treatment for you.
At the Law Offices of David L. Hood, we fight for the rights of the disabled. If you are considering a Social Security disability application or appeal, schedule a free consultation with us today at no risk to you. We handle all SSD cases on a contingent fee basis, which means you won’t pay attorney’s fees unless we help you receive benefits.
*Clients are not liable for any expenses, unless there is a recovery in their case; however, if there is a recovery in their case, clients will be liable for expenses. Attorney’s fees are based on a percentage of the recovery, which will be computed before deducting expenses.
Other online resources used in this article: